Get the Stockscreener App
25.08
2.98%
-0.76
Lyell Immunopharma Inc stock is traded at $25.08, with a volume of 32,273.
It is down -2.98% in the last 24 hours and down -32.84% over the past month.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
See More
Previous Close:
$25.84
Open:
$25.81
24h Volume:
32,273
Relative Volume:
0.43
Market Cap:
$529.19M
Revenue:
$54,000
Net Income/Loss:
$-210.26M
P/E Ratio:
-31.75
EPS:
-0.79
Net Cash Flow:
$-159.01M
1W Performance:
+5.51%
1M Performance:
-32.84%
6M Performance:
+128.11%
1Y Performance:
+114.56%
1-Day Range:
$24.87
$25.92
1-Week Range:
$22.67
$27.89
52-Week Range:
$7.65
$45.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Name
Lyell Immunopharma Inc
Sector
Industry
Phone
650 695-0677
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
24.91 | 548.94M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.03 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.27 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
816.66 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.64 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.31 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-30-24 | Downgrade | BofA Securities | Buy → Underperform |
| Jun-27-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-17-22 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | BofA Securities | Buy |
| Jul-12-21 | Initiated | Goldman | Buy |
| Jul-12-21 | Initiated | JP Morgan | Overweight |
| Jul-12-21 | Initiated | Morgan Stanley | Overweight |
View All
Lyell Immunopharma Inc Stock (LYEL) Latest News
Lyell Immunopharma (NASDAQ:LYEL) Shares Gap UpShould You Buy? - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Trading 13.4% HigherWhat's Next? - MarketBeat
Earnings Beat: How volatile is Lyell Immunopharma Inc stock2025 Technical Patterns & Smart Allocation Stock Tips - baoquankhu1.vn
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Update - Defense World
Lyell Immunopharma (NASDAQ:LYEL) Trading Up 7.3%What's Next? - MarketBeat
Entry Recap: Will Lyell Immunopharma Inc benefit from rate cutsExit Point & AI Forecast for Swing Trade Picks - baoquankhu1.vn
EPS Watch: What is the long term forecast for Lyell Immunopharma Inc stockPrice Action & Advanced Technical Signal Analysis - baoquankhu1.vn
How rising interest rates impact Lyell Immunopharma Inc. stock2025 Major Catalysts & AI Optimized Trading Strategy Guides - Улправда
Will Lyell Immunopharma Inc. stock benefit from automation2025 Price Targets & Fast Entry Momentum Trade Alerts - ulpravda.ru
Lyell Immunopharma (NASDAQ:LYEL) Shares Down 4.6%Here's Why - MarketBeat
Should I hold or sell Lyell Immunopharma Inc. stock in 2025Market Profile Overview & Low Cost Wealth Investment - bollywoodhelpline.com
Lyell Immunopharma (NASDAQ:LYEL) Shares Up 4.2%Still a Buy? - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Trading Down 6.7% – Should You Sell? - Defense World
Lyell Immunopharma (NASDAQ:LYEL) Shares Down 6.7%Here's Why - MarketBeat
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar - sharewise.com
Critical Review: Lipocine (NASDAQ:LPCN) & Lyell Immunopharma (NASDAQ:LYEL) - Defense World
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow - Yahoo Finance
Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data (NASDAQ:LYEL) - Seeking Alpha
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge - GlobeNewswire
Lyell Immunopharma (NASDAQ:LYEL) Shares Up 5.5%Here's Why - MarketBeat
Lyell ImmunoPharma pops on recent ASH data, immunotherapy expansion - MSN
Lyell Immunopharma (NASDAQ:LYEL) Reaches New 1-Year HighTime to Buy? - MarketBeat
Lyell Immunopharma pops on recent ASH data, immunotherapy expansion - Seeking Alpha
Why Lyell Immunopharma Inc. stock could be next big winnerPortfolio Growth Summary & High Win Rate Trade Tips - Улправда
Will Lyell Immunopharma Inc. stock rally after Fed decisionsGold Moves & High Accuracy Swing Trade Signals - Улправда
Would You Still Hold Lyell Immunopharma Stock If It Fell 30%? - Trefis
Dip Buying: Is Lyell Immunopharma Inc. stock a smart buy before Fed meeting2025 Market Trends & Free Expert Verified Stock Movement Alerts - Улправда
What technical charts say about Lyell Immunopharma Inc. stock2025 Trading Recap & Risk Controlled Stock Pick Alerts - DonanımHaber
What analysts say about Lyell Immunopharma Inc stockGap Up/Gap Down Analysis & Free Rapid Wealth Building - earlytimes.in
CEO Change: Why Lyell Immunopharma Inc. stock could be next big winnerBond Market & Consistent Profit Trading Strategies - Улправда
Can Lyell Immunopharma Inc. stock reach $100 price target2025 Earnings Impact & Daily Profit Focused Screening - DonanımHaber
Is Lyell Immunopharma Inc. stock a safe buy before earningsPortfolio Gains Summary & AI Powered Buy and Sell Recommendations - Улправда
Why Lyell Immunopharma Inc. stock could outperform in 20252025 Major Catalysts & Intraday High Probability Setup Alerts - DonanımHaber
Is Lyell Immunopharma Inc. stock a smart buy before Fed meetingJuly 2025 Chart Watch & Technical Pattern Recognition Alerts - Улправда
Lyell Immunopharma (LYEL) details 1.9M-share ICT resale and license terms - Stock Titan
Institutional investors are Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) biggest bettors and were rewarded after last week's US$72m market cap gain - Yahoo Finance
Lyell Immunopharma climbs after reporting strong CAR T-cell therapy results - MSN
China Universal Asset Management Co. Ltd. Has $26,000 Position in Lyell Immunopharma, Inc. $LYEL - Defense World
HSG Holding Ltd Cuts Position in Lyell Immunopharma, Inc. $LYEL - MarketBeat
1,820,634 Shares in Lyell Immunopharma, Inc. $LYEL Bought by ARCH Venture Management LLC - MarketBeat
Lyell ImmunoPharma announces new data from trial of rondecabtagene autoleucel - MSN
Lyell Immunopharma (NASDAQ:LYEL) Sets New 12-Month HighShould You Buy? - MarketBeat
Aug Technicals: Why Lyell Immunopharma Inc stock could outperform in 2025Weekly Gains Summary & Smart Swing Trading Alerts - moha.gov.vn
Lyell Immunopharma (NASDAQ:LYEL) Trading Up 11.4%Should You Buy? - MarketBeat
100,000 Shares in Lyell Immunopharma, Inc. $LYEL Bought by RBF Capital LLC - MarketBeat
Lyell Immunopharma Shares Rise After HC Wainwright Upgrade - marketscreener.com
H.C. Wainwright upgrades Lyell to 'buy' on cell therapy progression - TradingView — Track All Markets
Lyell Immunopharma (LYEL) price target increased by 35.71% to 19.38 - MSN
This Eaton Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors - GlobeNewswire Inc.
LYEL Analyst Rating Upgrade: HC Wainwright & Co. Sets New Price Target | LYEL Stock News - GuruFocus
Lyell Immunopharma Inc Stock (LYEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.27%
2.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):